Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib

Aim: Apatinib is an orally administered vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitors approved for the treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma. Apatinib is predominantly metabolized by CYP3A4/5, followed by CYP2D6. The...

Full description

Bibliographic Details
Main Authors: Hongrui Liu, Yiqun Yu, Nan Guo, Xiaojuan Wang, Bing Han, Xiaoqiang Xiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Pharmacology
Subjects:
apatinib
tyrosine kinase inhibitors (TKIs)
physiologically based pharmacokinetic (PBPK) models
drug–drug interaction (DDI)
drug-disease interaction (DDZI)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.780937/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.780937/full

Similar Items